TNSN96104A1 - Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant - Google Patents

Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant

Info

Publication number
TNSN96104A1
TNSN96104A1 TNTNSN96104A TNSN96104A TNSN96104A1 TN SN96104 A1 TNSN96104 A1 TN SN96104A1 TN TNSN96104 A TNTNSN96104 A TN TNSN96104A TN SN96104 A TNSN96104 A TN SN96104A TN SN96104 A1 TNSN96104 A1 TN SN96104A1
Authority
TN
Tunisia
Prior art keywords
phenylpiperidine
trihydrate
hydroxyphenyl
propanol
hydroxy
Prior art date
Application number
TNTNSN96104A
Other languages
English (en)
Inventor
Maria Andino Marta
Gene Sinay Terry
Fred Fiese Eugene
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN96104A1 publication Critical patent/TNSN96104A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

L’INVENTION CONCERNE LE TRIHYDRATE DU MESYLATE DE (1S, 2S)- 1- (4-HYDROXYPHENYL) -2-(4-HYDROXY-4-PHENYLPIPERIDINE-1-YL)-1-PROPANOL . ELLE CONCERNE EGALEMENT DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CE COMPOSE. APPLICATION : METHODES D'UTILISATION DE CE COMPOSE POUR LE TRAITEMENT D'AFFECTIONS DU SNC.
TNTNSN96104A 1995-08-11 1996-08-07 Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant TNSN96104A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11

Publications (1)

Publication Number Publication Date
TNSN96104A1 true TNSN96104A1 (fr) 2005-03-15

Family

ID=21699847

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN96104A TNSN96104A1 (fr) 1995-08-11 1996-08-07 Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant

Country Status (41)

Country Link
US (1) US6008233A (fr)
EP (1) EP0843661B1 (fr)
JP (1) JP3099072B2 (fr)
KR (1) KR100291882B1 (fr)
CN (2) CN1615861A (fr)
AP (1) AP755A (fr)
AR (1) AR004676A1 (fr)
AT (1) ATE215072T1 (fr)
AU (1) AU710984B2 (fr)
BG (1) BG63678B1 (fr)
BR (1) BR9610766A (fr)
CA (1) CA2228752C (fr)
CO (1) CO4750830A1 (fr)
CZ (1) CZ296236B6 (fr)
DE (1) DE69620191T2 (fr)
DK (1) DK0843661T3 (fr)
DZ (1) DZ2083A1 (fr)
ES (1) ES2170857T3 (fr)
GT (1) GT199600051A (fr)
HR (1) HRP960372B1 (fr)
HU (1) HUP9802862A3 (fr)
IL (1) IL122649A (fr)
IS (1) IS1945B (fr)
MA (1) MA23957A1 (fr)
NO (1) NO310458B1 (fr)
NZ (1) NZ309134A (fr)
OA (1) OA10664A (fr)
PE (1) PE4898A1 (fr)
PL (1) PL185603B1 (fr)
PT (1) PT843661E (fr)
RO (1) RO120134B1 (fr)
RS (1) RS49521B (fr)
RU (1) RU2140910C1 (fr)
SA (1) SA96170171B1 (fr)
SK (1) SK284209B6 (fr)
TN (1) TNSN96104A1 (fr)
TR (1) TR199800208T1 (fr)
TW (1) TW495502B (fr)
UA (1) UA59341C2 (fr)
WO (1) WO1997007098A1 (fr)
ZA (1) ZA966760B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531154T2 (de) * 1994-08-18 2004-04-08 Pfizer Inc. Neuroprotektive 3-(piperidinyl-1)-chroman-4,7-diol und 1-(4-hyphoxyphenyl)-2-(piperidinyl-1)-alkanolderivate
EP0843661B1 (fr) * 1995-08-11 2002-03-27 Pfizer Inc. Trihydrate de methanesulfonate de (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU3676100A (en) * 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27801A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
YU27701A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
IL154378A0 (en) * 2000-08-16 2003-09-17 Upjohn Co Compounds for the treatment of addictive disorders
EP1186303A3 (fr) * 2000-09-06 2003-12-10 Pfizer Products Inc. Combinaisons pharmaceutiques pour le traitement des accidents cerebrovasculaires, contenant un facteur inhibitant la neutrophile et un antagoniste selectif du NMDA-NR2B
EP1674087A1 (fr) 2000-10-02 2006-06-28 Pfizer Products Inc. Utilisation prophylactique d'antagonistes des récepteurs du N-méthyl-D-aspartate (NMDA)
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
NZ532328A (en) * 2001-10-19 2005-07-29 Toyama Chemical Co Ltd Alkyl ether derivatives or salts thereof
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
BRPI0617852A2 (pt) 2005-10-25 2011-08-09 Shionogi & Co compostos derivados de aminodi-hidrotiazina assim como composições contendo os mesmos
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
WO2008133273A1 (fr) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Composition pharmaceutique pour le traitement de la maladie d'alzheimer
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
CA2783958A1 (fr) 2009-12-11 2011-06-16 Shionogi & Co., Ltd. Derive d'oxazine
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
EP2703399A4 (fr) 2011-04-26 2014-10-15 Shionogi & Co Dérivé d'oxazine et inhibiteur de bace 1 le contenant
EP2912035A4 (fr) 2012-10-24 2016-06-15 Shionogi & Co Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
DK3194403T3 (en) 2014-09-15 2019-04-15 Rugen Holdings Cayman Ltd PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS
EP3197440A4 (fr) * 2014-09-22 2018-04-18 Rugen Holdings (Cayman) Limited Traitement des troubles de l'anxiété et des troubles du spectre autistique
EP3253761A4 (fr) 2015-02-04 2018-06-20 Rugen Holdings (Cayman) Limited Dérivés 3,3-difluoro-pipéridine en tant qu'antagonistes des récepteurs nmda nr2b
KR102613179B1 (ko) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물
WO2018098128A1 (fr) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Traitement de troubles du spectre autistique, de troubles obsessivo-compulsifs et de troubles de l'anxiété

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
WO1990014087A1 (fr) * 1989-05-17 1990-11-29 Pfizer Inc. Derives de 2-piperidino-1-alcanol en tant qu'agents antiischemiques
DE69531154T2 (de) * 1994-08-18 2004-04-08 Pfizer Inc. Neuroprotektive 3-(piperidinyl-1)-chroman-4,7-diol und 1-(4-hyphoxyphenyl)-2-(piperidinyl-1)-alkanolderivate
EP0843661B1 (fr) * 1995-08-11 2002-03-27 Pfizer Inc. Trihydrate de methanesulfonate de (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol

Also Published As

Publication number Publication date
DK0843661T3 (da) 2002-07-22
NZ309134A (en) 1999-09-29
AR004676A1 (es) 1999-03-10
AP9600856A0 (en) 1996-10-31
TR199800208T1 (fr) 1998-05-21
WO1997007098A1 (fr) 1997-02-27
ZA966760B (en) 1998-02-09
HRP960372A2 (en) 1998-04-30
PL185603B1 (pl) 2003-06-30
CZ296236B6 (cs) 2006-02-15
DZ2083A1 (fr) 2002-10-23
CZ39098A3 (cs) 1999-02-17
RS49521B (sr) 2006-10-27
IS4643A (is) 1997-12-30
CN1615861A (zh) 2005-05-18
PL325050A1 (en) 1998-07-06
PT843661E (pt) 2002-07-31
AU5908496A (en) 1997-03-12
CO4750830A1 (es) 1999-03-31
SK284209B6 (en) 2004-11-03
EP0843661A1 (fr) 1998-05-27
BG63678B1 (bg) 2002-09-30
JPH10510552A (ja) 1998-10-13
IS1945B (is) 2004-08-13
SA96170171B1 (ar) 2006-05-20
SK16698A3 (en) 1999-06-11
MA23957A1 (fr) 1997-04-01
YU46196A (sh) 1999-07-28
RO120134B1 (ro) 2005-09-30
CA2228752C (fr) 2002-12-10
CA2228752A1 (fr) 1997-02-27
DE69620191T2 (de) 2002-07-18
HUP9802862A3 (en) 1999-05-28
NO310458B1 (no) 2001-07-09
HUP9802862A2 (hu) 1999-04-28
IL122649A0 (en) 1998-08-16
AP755A (en) 1999-08-02
DE69620191D1 (de) 2002-05-02
ATE215072T1 (de) 2002-04-15
IL122649A (en) 2001-08-26
KR19990036321A (ko) 1999-05-25
JP3099072B2 (ja) 2000-10-16
ES2170857T3 (es) 2002-08-16
MX9801149A (es) 1998-05-31
US6008233A (en) 1999-12-28
NO980574D0 (no) 1998-02-10
GT199600051A (es) 1997-12-26
PE4898A1 (es) 1998-03-16
CN1198739A (zh) 1998-11-11
OA10664A (en) 2000-11-06
EP0843661B1 (fr) 2002-03-27
UA59341C2 (uk) 2003-09-15
BG102289A (en) 1998-09-30
NO980574L (no) 1998-02-10
AU710984B2 (en) 1999-10-07
BR9610766A (pt) 1999-07-13
HRP960372B1 (en) 2003-04-30
TW495502B (en) 2002-07-21
KR100291882B1 (ko) 2001-10-26
RU2140910C1 (ru) 1999-11-10

Similar Documents

Publication Publication Date Title
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97139A1 (fr) Derives d'acides d'arylsulfonylaminohydroxamiques
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN98238A1 (fr) Macrolides nouveaux
TNSN96085A1 (fr) Amides therapeutiques et compositions les contenant
BE1002249A4 (fr) Compositions pharmaceutiques.
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98150A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98140A1 (fr) Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00231A1 (fr) Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN98022A1 (fr) DERIVES DE N-HYDROXY-β-SULFONYLPROPIONAMIDE, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
DZ2752A1 (fr) Composés et compositions pharmaceutiques pour le traitement du paludisme.